Novartis has ended work on ianalumab in a painful skin condition after the monoclonal antibody failed to meet “predefined ...

One of the world’s biggest genetic databases comprises DNA data donated over the years by more than a million retired ...

Otsuka Pharmaceutical is putting down $33 million cash for a Swedish biotech’s IL1RAP antibodies designed to treat autoimmune ...

Patients with a mysterious eye pain disease may be one step closer to seeing the first approved treatment for their condition ...

Momentum in Johnson & Johnson’s cardiovascular business continues, while the company looks to regain its footing in the ...

The National Institutes of Health (NIH) has fired its chief operating officer amid a probe into whether his wife could have ...

Alphabet spinoff SandboxAQ is teaming up with iOncologi to build a new mRNA vaccine for a common and aggressive brain tumor ...

The artificial intelligence-powered spine surgery developer Carlsmed is showing some backbone as it kicks off its IPO, with ...

This story was updated at 5:30 p.m. ET to include comment from an investor call.   | Sarepta Therapeutics has laid off 500 staffers, or 36% of its workforce, as part of a strategic restructuring ...

Following two rounds of pipeline prioritizations in a year, Repare reaffirmed this morning that it is focused on a pair of ...

The FDA has lifted one of the two clinical holds placed on Kezar Life Sciences’ zetomipzomib, leading the biotech to speculate on whether to reignite another program for the same drug that remains ...

AstraZeneca’s plans to get an amyloidosis drug to market look further out of reach after the pharma’s anti-fibril antibody failed to reduce deaths and hospitalizations in a key phase 3 study. | ...